BiotechTube

Pimavanserin

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Conditions

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Trial Timeline

Jul 17, 2018 → May 5, 2023

NCT ID
NCT03623321

About Pimavanserin

Pimavanserin is a phase 3 stage product being developed by Acadia Pharmaceuticals for Neuropsychiatric Symptoms Related to Neurodegenerative Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03623321. Target conditions include Neuropsychiatric Symptoms Related to Neurodegenerative Disease.

What happened to similar drugs?

1 of 2 similar drugs in Neuropsychiatric Symptoms Related to Neurodegenerative Disease were approved

Approved (1) Terminated (0) Active (1)
✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved
🔄Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT05796167Phase 1Withdrawn
NCT05357612ApprovedRecruiting
NCT04809116ApprovedWithdrawn
NCT05555615Phase 2/3Terminated
NCT04292223ApprovedCompleted
NCT04000009Phase 3Terminated
NCT03623321Phase 3Completed
NCT03482882Phase 2Completed
NCT03118947Phase 2Completed
NCT03121586Phase 3Terminated
NCT03018340Phase 2Completed

Competing Products

2 competing products in Neuropsychiatric Symptoms Related to Neurodegenerative Disease

See all competitors
ProductCompanyStageHype Score
Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved
44
Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3
37